Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy-Reference-Cited by-同舟云学术

Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy

Published:2017-07-25 Issue:41 Volume:8 Page:71249-71284
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Medrano Ruan F.V.¹,Hunger Aline¹,Mendonça Samir Andrade¹,Barbuto José Alexandre M.²³,Strauss Bryan E.¹

Affiliation:

1. Viral Vector Laboratory, Center for Translational Investigation in Oncology, Cancer Institute of São Paulo/LIM 24, University of São Paulo School of Medicine, São Paulo, Brazil

2. Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

3. Cell and Molecular Therapy Center, NUCEL-NETCEM, University of São Paulo, São Paulo, Brazil

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impaired activation of plasmacytoid dendritic cells via toll-like receptor 7/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift;Frontiers in Immunology;2024-01-03

2. Tumour cells can escape antiproliferative pressure by interferon-β through immunoediting of interferon receptor expression;Cancer Cell International;2023-12-08

3. Editorial: Interferons: key modulators of the immune system in cancer;Frontiers in Immunology;2023-11-08

4. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses;Frontiers in Immunology;2023-10-31

5. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial;Nature Communications;2023-10-24